- Home
- LXP vs GLPG Comparison
LXP vs GLPG Comparison
Compare LXP & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXP
- GLPG
- Stock Information
- Founded
- LXP 1993
- GLPG 1999
- Country
- LXP United States
- GLPG Belgium
- Employees
- LXP N/A
- GLPG N/A
- Industry
- LXP Real Estate Investment Trusts
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- LXP Real Estate
- GLPG Health Care
- Exchange
- LXP Nasdaq
- GLPG Nasdaq
- Market Cap
- LXP 2.5B
- GLPG 2.1B
- IPO Year
- LXP 1993
- GLPG 2005
- Fundamental
- Price
- LXP $9.11
- GLPG $32.26
- Analyst Decision
- LXP Hold
- GLPG Sell
- Analyst Count
- LXP 3
- GLPG 4
- Target Price
- LXP $10.50
- GLPG $25.33
- AVG Volume (30 Days)
- LXP 2.7M
- GLPG 168.5K
- Earning Date
- LXP 11-05-2025
- GLPG 10-29-2025
- Dividend Yield
- LXP 5.89%
- GLPG N/A
- EPS Growth
- LXP 203.57
- GLPG N/A
- EPS
- LXP 0.27
- GLPG N/A
- Revenue
- LXP $363,003,000.00
- GLPG $323,674,692.00
- Revenue This Year
- LXP N/A
- GLPG N/A
- Revenue Next Year
- LXP $5.19
- GLPG N/A
- P/E Ratio
- LXP $33.93
- GLPG N/A
- Revenue Growth
- LXP 6.63
- GLPG 5.43
- 52 Week Low
- LXP $6.85
- GLPG $22.36
- 52 Week High
- LXP $10.33
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- LXP 60.53
- GLPG 51.29
- Support Level
- LXP $9.10
- GLPG $31.49
- Resistance Level
- LXP $9.28
- GLPG $33.63
- Average True Range (ATR)
- LXP 0.16
- GLPG 0.66
- MACD
- LXP -0.01
- GLPG -0.06
- Stochastic Oscillator
- LXP 50.88
- GLPG 50.18
About LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.